ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of

ADDEX THERAPEUTICS LTD

INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Balance

as of September 30, 2021, and December 31,

The accompanying notes form an integral part of

these consolidated financial statements.

Interim Condensed Consolidated Financial Statements 3

Unaudited Interim Condensed Consolidated Statements

of Comprehensive Loss

for the three-month and nine-month periods

ended September 30, 2021 and 2020

The accompanying notes form an integral part of

these consolidated financial statements.

Addex Therapeutics Interim Condensed

Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Changes in Equity

For the nine-month periods ended September

The accompanying notes form an integral part of

these consolidated financial statements.

Addex Therapeutics Interim Condensed

Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Changes in Equity

For the three-month period ended September

The accompanying notes form an integral part of

these consolidated financial statements.

Addex Therapeutics Interim Condensed

Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Changes in Equity

For the three-month period ended September

The accompanying notes form an integral part of

these consolidated financial statements.

Addex Therapeutics Interim Condensed

Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

for the nine-month periods ended September

The accompanying notes form an integral part of

these consolidated financial statements.

Unaudited Notes to the Interim Condensed Consolidated

Financial Statements

for the three-month and nine-month periods

ended September 30, 2021

(Amounts in Swiss francs)

1. General information

Addex Therapeutics Ltd (the "Company"), formerly Addex

Pharmaceuticals Ltd, and its subsidiaries (together, the "Group") are a clinical stage pharmaceutical group applying its

leading allosteric modulator drug discovery platform to discovery and development of small molecule pharmaceutical products, with an

initial focus on central nervous system disorders.

The Company is a Swiss stockholding corporation domiciled c/o Addex

Pharma SA, Chemin des Aulx 12, CH1228 Plan-les-Ouates, Geneva, Switzerland and the parent company of Addex Pharma SA, Addex Pharmaceuticals

France SAS and Addex Pharmaceuticals Inc. registered in Delaware with its principal business location in San Francisco, California, United

States. Its registered shares are traded at the SIX, Swiss Exchange, under the ticker symbol ADXN. On January 29, 2020, the Group listed

on the Nasdaq Stock Market, American Depositary Shares (ADSs) under the symbol "ADXN", without a new issuance of securities.

ADSs represents shares that continue to be admitted to trading on SIX Swiss Exchange.

These condensed consolidated financial statements have been approved

for issuance by the Board of Directors on November 3, 2021.

2. Basis of preparation

These condensed consolidated interim financial statements for the

three-month and nine-month periods ended September 30, 2021, have been prepared under the historic cost convention and in accordance

with IAS 34 "Interim Financial Reporting" and are presented in a format consistent with the consolidated financial statements

under IAS 1 "Presentation of Financial Statements". However, they do not include all of the notes that would be required

in a complete set of financial statements. Thus, this interim financial report should be read in conjunction with the consolidated financial

statements for the year ended December 31, 2020.

Interim financial results are not necessarily indicative of results

anticipated for the full year. The preparation of these unaudited condensed consolidated interim financial statements made in accordance

with IAS 34 requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of

contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the

reporting period. Although these estimates are based on management's best knowledge of current events and actions, actual results

ultimately may differ from those estimates. The areas involving a higher degree of judgment which are significant to the condensed consolidated

interim financial statements are disclosed in note 4 to the consolidated financial statements for the year ended December 31, 2020.

A number of new or amended standards and interpretations became applicable

for financial periods beginning on or after January 1, 2021. The Group noted that the latter did not have a material impact on the Group's

financial position or disclosures made in the condensed consolidated interim financial statements.

Due to rounding, numbers presented throughout these condensed consolidated

financial statements may not add up precisely to the totals provided. All ratios and variances are calculated using the underlying amount

rather than the presented rounded amount.

3. Critical accounting estimates and judgments

The Group makes estimates and assumptions concerning the future. These

estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of

future events that are believed to be reasonable under the circumstances. The resulting accounting estimates will, by definition, seldom

equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the

carrying amounts of assets and liabilities or may have had a significant impact on the reported results are disclosed below:

The Group's accounts are prepared on a going concern basis.

To date, the Group has financed its cash requirements primarily from share issuances and licensing certain of its research and development

stage products. The Group is a development-stage enterprise and is exposed to all the risks inherent in establishing a business. The

Group expects that its existing cash and cash equivalents will be sufficient to fund its operations and meet all of its obligations as

they fall due for at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements. The

future viability of the Group is dependent on its ability to raise additional capital to finance its future operations that may be delayed

due to COVID 19 pandemic. The Group will seek additional funding through public or private financings or collaboration agreements. The